基因編輯技術合作與授權協議（2016-2025）

本報告全面深入分析了基因編輯技術合作與授權協議，讓您以前所未有的方式了解全球領先的生物製藥公司簽署的基因編輯技術相關協議。

這份經過全面修訂和更新的報告詳細介紹了2016年至2025年的基因編輯交易。

本報告詳細分析了公司簽署基因編輯協議的原因和方式。這些協議通常包含多個要素，涵蓋合作研發到成果商業化等各個面向。

本報告涵蓋合作研究、開發、探索和授權。

本報告包​​含自2016年以來公佈的384項基因編輯交易的完整列表，其中包括可用的財務條款以及各方披露的實際基因編輯合作的在線記錄鏈接。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的前幾章概述了基因編輯領域的交易情況。

第一章概述了本報告。

第二章概述了自 2016 年以來的基因編輯交易情況。

第三章概述了自 2016 年以來主要的基因編輯交易，並依交易總額列出。

第四章提供了基因編輯領域交易活動最活躍的前 25 家公司的完整名單，以及簡要概述和基因編輯交易及公開合約文件的完整清單。

第五章對自 2016 年 1 月以來已完成和已宣布的、且有公開合約文件的基因編輯交易進行了全面深入的審查。

第六章對自2016年1月以來簽署和公佈的基因編輯領域合作協議進行了全面深入的回顧。本章依所涵蓋的具體基因編輯技術類型進行組織。

本報告也包含大量表格和圖表，展示了自2016年以來基因編輯交易的趨勢和活動。

此外，我們還提供了一個全面的合約目錄，依公司名稱（A-Z）、合約類型和治療標靶進行組織。每個合約標題都透過網路連結指向合約記錄的線上版本，並在可用的情況下指向合約文件，以便根據需要輕鬆存取每個合約文件。

主要優勢

"基因編輯領域的研究合作與授權協議" 報告提供讀者以下主要優勢：

• 了解自 2016 年以來的交易趨勢
• 查看基因編輯領域的合作與授權協議
• 基準分析 - 確定交易的市場價值
• 財務條款 - 首付款、里程碑付款、特許權使用費
• 依公司（A-Z）、協議類型和治療領域列出交易
• 以價值為排名的熱門交易
• 最活躍的交易撮合者
• 確定每筆交易的資產和條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作公司的適用性
• 節省數百小時的研究時間

範圍

• "基因編輯合作與授權協議" 旨在幫助讀者深入了解基因編輯領域以及全球領先的生物製藥公司正在簽署的協議結構。

本報告內容

• 生物製藥產業基因編輯交易趨勢
• 製藥和生物技術公司基因編輯交易記錄目錄
• 依金額排名的主要基因編輯交易
• 最活躍的基因編輯授權協議公司
• "基因編輯合作與許可協議" 提供對現有協議記錄的全面訪問，包括合約文件（如有）。

對協議的分析有助於對以下方面進行盡職調查：

• 協議具體授予或選擇哪些權利？
• 協議實際授予合作公司哪些權利？
• 授予了哪些獨家經營權？
• 交易的付款結構是什麼？
• 如何進行銷售和付款審計？
• 合約期限是多久？
• 如何定義協議的關鍵條款？
• 如何處理和歸屬知識產權？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止協議？
• 如果所有權發生變更，會發生什麼事？
• 如何約定轉讓許可和分包條款？
• 貴公司要求使用哪些標準條款？
• 哪些標準條款會因交易對手和交易類型而異？
• 貴公司必須遵守哪個司法管轄區的法律？

目錄

摘要整理

第一章：引言

第二章：基因編輯交易趨勢

• 引言
• 歷年基因編輯交易
• 最活躍的基因編輯交易商
• 以交易類型劃分的基因編輯交易
• 依治療領域劃分的基因編輯交易
• 依行業劃分的基因編輯交易
• 基因編輯交易條款
  • 基因編輯交易的關鍵價值
  • 基因編輯交易中的預付款
  • 基因編輯交易中的里程碑付款
  • 基因編輯專利費率

第三章：基因編輯的關鍵要素交易

• 引言
• 以價值排名的頂級基因編輯交易

第四章 - 最活躍的基因編輯經銷商

• 引言
• 最活躍的基因編輯經銷商
• 最活躍的基因編輯經銷商公司簡介

第五章 - 基因編輯合約交易目錄

• 引言
• 基因編輯合約交易目錄

第六章 - 以技術類型劃分的基因編輯交易

• 交易目錄
• 依公司劃分的基因編輯交易目錄 (AZ)
• 以交易類型劃分的基因編輯交易目錄
• 依治療領域劃分的基因編輯交易目錄
• 交易類型定義
• 關於研究公司
• 當前合作夥伴關係
• 當前合約
• 當前合作夥伴關係近期報告標題

Gene Editing Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene editing deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene editing deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter gene editing deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 384 gene editing deals announced since 2016 including financial terms where available including links to online deal records of actual gene editing partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene editing dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene editing dealmaking since 2016.

Chapter 3 provides an overview of the leading gene editing deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene editing dealmaking with a brief summary followed by a comprehensive listing of gene editing deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene editing deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of gene editing partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene editing technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene editing deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Editing Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse gene editing collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Gene Editing Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene editing trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Editing Collaboration and Licensing Deals includes:

• Trends in gene editing dealmaking in the biopharma industry
• Directory of gene editing deal records covering pharmaceutical and biotechnology
• The leading gene editing deals by value
• Most active gene editing licensing dealmakers
• Gene Editing Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in gene editing dealmaking

• 2.1. Introduction
• 2.2. Gene editing deals over the years
• 2.3. Most active gene editing dealmakers
• 2.4. Gene editing deals by deal type
• 2.5. Gene editing deals by therapy area
• 2.6. Gene editing deals by industry sector
• 2.7. Deal terms for gene editing deals
  • 2.7.1 Gene editing deals headline values
  • 2.7.2 Gene editing deal upfront payments
  • 2.7.3 Gene editing deal milestone payments
  • 2.7.4 Gene editing royalty rates

Chapter 3 - Leading gene editing deals

• 3.1. Introduction
• 3.2. Top gene editing deals by value

Chapter 4 - Most active gene editing dealmakers

• 4.1. Introduction
• 4.2. Most active gene editing dealmakers
• 4.3. Most active gene editing deals company profiles

Chapter 5 - Gene editing contracts dealmaking directory

• 5.1. Introduction
• 5.2. Gene editing contracts dealmaking directory

Chapter 6 - Gene editing dealmaking by technology type

• Deal directory
• Deal directory - Gene editing deals by company A-Z
• Deal directory - Gene editing deals by deal type
• Deal directory - Gene editing deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Gene editing deals since 2016
• Figure 2: Active gene editing dealmaking activity - 2016 - 2025
• Figure 3: Gene editing deals by deal type since 2016
• Figure 4: Gene editing deals by therapy area since 2016
• Figure 5: Gene editing deals by industry sector since 2016
• Figure 6: Gene editing deals with a headline value
• Figure 7: Gene editing deals with an upfront value
• Figure 8: Gene editing deals with a milestone value
• Figure 9: Gene editing deals with a royalty rate value
• Figure 10: Top gene editing deals by value since 2016
• Figure 11: Most active gene editing dealmakers 2016 - 2025
• Figure 12: Gene editing deals by technology type since 2016